Alzheimer's and Huntington as Neurodegenerative Diseases

References

1. Shamim IA. Neurodegenerative Diseases. New York: Springer; 2012.
2. Avila J, Lucas J, Hernandes F. Animal Models for Neurodegenerative Disease. Cambridge: The Royal Society of Chemistry; 2011.
3. Hardiman O, Doherty CP, Elamin M, Bede P. Neurodegenerative Disorders. Switzerland: Springer International Publishing; 2016.
4. Cankurtaran M, Arıo¤ul S. Alzheimer hastalı¤ı ve demans tedavisinde yenilikler. Türkiye Tıp Dergisi 2002; 9:128-36.
5. Perl DP. Neuropathology of Alzheimer's Disease. Mt Sinai J Med 2010;77:32-42
6. Şahin Ş. Deneysel Alzheimer Hastalı¤ı Modelleri. Turkiye Klinikleri Journal of Neurology Special Topics 2012;5:102-6.
7. Puzzo D, Gulisano W, Palmeri A, Arancio O. Rodent models for Alzheimer's disease drug discovery. Expert Opin Drug Discov 2015;10:703-11.
8. Chesselet MF, Carmichael ST. Animal models of neurological disorders. Neurotherapeutics 2012;9:241-4.
9. Bajo R, Pusil S, López ME, Canuet L, Pereda E, Osipova D, et al. Scopolamine effects on functional brain connectivity: a pharmacological model of Alzheimer's disease. Sci Rep 2015;5:9748.
10. McGowan E, Eriksen J, Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 2006;22:281-9.
11. Ersoy N, Başak AN. Molecular Biology of Huntington's Disease. Turk J Neurol 2005;11:27-44.
12. Pouladi MA, Morton AJ, Hayden MR. Choosing an animal model for the study of Huntington's disease. Nature Reviews. Neuroscience 2013;14:708–21.
13. Li JY, Popovic N, Brundin P. The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx 2005;2:447–64.

Cited by

3 — Crossref — cited-by count (retrieved 2 Oct 2026, source)

Citation counts are shown with their source and retrieval date. They are not an Impact Factor or any journal-level metric.